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Abstract
Interleukin 13 (IL13) binds a receptor that is highly
overexpressed in malignant gliomas, IL13RA2. IL13
protein is composed of four helices: A-helix A, B, C,
and D, and we found a new ‘‘hot spot’’ in A-helix D
that is crucial for the binding of IL13 to IL13RA2. Lys-
105 plus Lys-106 and Arg-109 represent this hot spot.
In the current study, we have made substitutions at
these three positions in IL13. We examined both
neutralization of an IL13-based cytotoxin’s glioma cell
killing and direct receptor binding of the new IL13
mutants. We observed that Lys-105 and Arg-109 are
critical for IL13 binding to IL13Ra2, indeed. However,
new mutants of important properties were identified
with regard to tumor targeting. IL13.K105R mutant, in
which lysine was substituted by arginine, neutralized
the killing of IL13Ra2-positive cells by IL13-based
cytotoxin more efficiently than wild-type IL13. How-
ever, IL13.K105L or IL13.K105A was deprived of any
such activity. Furthermore, IL13.K105R and
IL13.R109K competed 77- and 27-fold better, respec-
tively, with the binding of [125I]IL13 to the IL13Ra2
binding sites when compared with wild-type IL13.
Thus, we have uncovered the first forms of IL13 of
higher avidity toward IL13Ra2. These mutants should
prove useful in the further design of anticancer
diagnostics/therapeutics.
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Introduction
Interleukin 13 (IL13) is a cytokine that elicits both proin-
flammatory and anti-inflammatory immune responses [1,2].
IL13 is structurally homologous to IL4 and contains four
(A, B, C, and D) a-helices. IL13 and IL4 bind to IL13/4
receptor (IL13/4R), a heterodimeric receptor complex com-
posed of IL13Ra1 and IL4Ra, that is expressed in many
normal organs and in adenocarcinomas [3–5]. However,
IL13 binds malignant brain tumor (glioma) cells indepen-
dently of IL4, which indicated the existence of another
binding moiety specific for IL13 [6,7]. Subsequently, IL13
receptor a 2 (IL13Ra2) was cloned [8] and this monomeric
protein exhibits affinity for IL13, but not IL4. Our studies
revealed that malignant gliomas overexpress this restricted
receptor for IL13 and that IL13Ra2 is the molecular entity
responsible for the binding of IL13 to glioma tumors [9–13].
We have been analyzing the structure–function relationship
for the purpose of redirecting IL13 from its normal tissue re-
ceptor, IL13/4R, to the tumor-associated receptor, IL13Ra2
[14]. We demonstrated that residues in a-helix A (Pro-7 to
Gln-23), a-helix C (Ala-60 to Cys-72), and a-helix D (Lys-90 to
Glu-110) take part in the interactionwith both IL13Ra2 and IL13/
4R (Figure 1) [15–17]. For example, we discovered glutamic
acid at position 13 (a-helix A) to be a ‘‘hot spot’’ for IL13
interaction with IL13/4R, and it contributes to site I of the binding
regions in IL13 [17]. Thus, IL13 with mutation of the glutamic
acid at position 13 to lysine (IL13.E13K) does not bind nor
activate IL13/4R, but it retains avidity toward the glioma-re-
stricted IL13Ra2 [16]. Similarly, IL13.R66D and IL13.S69D
mutants (a-helix C) binding to the IL13/4R is altered without a
loss of its affinity toward the glioma-restricted receptor [17].
Hypothetically, site II of the IL13Ra2 binding region in IL13
was considered to be located in another helix, a-helix D, at the
C-terminal end of the cytokine [15]. Of interest, the first IL13
mutant in D helix, IL13.R109D, showed an impaired interaction
with glioma cells [17]. This experimental result strongly sup-
ported the notion of a-helix D belonging to the receptor binding
site II of IL13. However, no derivatives of IL13 were known with
selectively enhanced recognition of the IL13Ra2.
More recently, we performed alanine scanning of the entire
a-helix D segment of human IL13 in order to systematically
delineate the residues that take part in the binding to IL13Ra2
(Figure 1) [18]. Thus, we found that residues 105, 106, and 109
in the a-helix D region of IL13 form the interacting triad toward
the glioma-restricted receptor, a new receptor binding ‘‘hot
spot’’ in IL13 [18]. Moreover, we noted that these three resi-
dues are the only hydrophilic ones located in the amphipathic
middle region of a-helix D, comprising the motif LLLHLKKLFR
Abbreviations: CD, circular dichroism; FPLC, fast protein liquid chromatography; GBM,
glioblastoma multiforme; h, human; HGA, high-grade astrocytoma; IL4, interleukin 4; IL13,
interleukin 13; IPTG, isopropyl-1thio-h-D-galactopyranoside; m, murine; MTS, 3-(4,5-
dimethylthiazol-2yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt; PAGE, polyacrylamide gel electrophoresis; PE, Pseudomonas exotoxin; PMS, phenazine
methosulfate; SDS, sodium dodecyl sulfate
Address all correspondence to: Waldemar Debinski, MD, PhD, Department of Neurosurgery/
H110, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA
17033-0850, USA. E-mail: wdebinski@psu.edu
1This work was supported by NIH/NCI grant 2R01 CA 74145.
Received 30 July 2003; Revised 7 October 2003; Accepted 8 October 2003.
Copyright D 2004 Neoplasia Press, Inc. All rights reserved 1522-8002/04/$25.00
Neoplasia . Vol. 6, No. 1, January/February 2004, pp. 15 – 22 15
www.neoplasia.com
RESEARCH ARTICLE
(hydrophilic residues are in bold) (Figure 1) [18]. In our
present investigation, we have substituted amino acids at
positions 105, 106, and 109 in the a-helix D region with
amino acids other than alanine, based on the charge, chain
length, and bulkiness of the residues, and analyzed their
functional properties. In the course of this investigation, we
have identified the first mutants of IL13 of higher avidity
toward the IL13Ra2 when compared with wild-type cytokine.
Materials and Methods
Materials
The mutagenesis primers were synthesized in-house in
Macromolecular Core Laboratory, Pennsylvania State Uni-
versity College of Medicine (Hershey, PA). Fast protein liquid
chromatography (FPLC), columns and media, and unique
site elimination mutagenesis kit were obtained from Amer-
sham Pharmacia Biotech (Piscataway, NJ). Glioblastoma
multiforme (GBM) (a grade IV astrocytoma) U-251 MG cell
line was from American Type Culture Collection (ATCC;
Rockville, MD). G-26 mouse glioma cells were transfected
with IL13Ra2 receptors to obtain G-26-IL13Ra2+ cells [11].
The TF-1 cell line was obtained from the ATCC. Tissue
culture equipment were from Corning Glass (Corning, NY).
3(4,5-Dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt/phenazine metho-
sulfate (MTS/PMS) was purchased from Promega (Madison,
WI). Sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) and Western blot transferring equipment
were from Bio-Rad (Hercules, CA). Antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Super-
Signal Substrate for chemiluminescent detection was from
Pierce (Rockford, IL). IODO-GEN reagent for 125I labeling
was purchased from Pierce.
Methods
Expression, purification, and structural characterization of
IL13 a-helix D mutants The plasmid was constructed with
T7 promoters and isopropyl-1thio-h-D-galactopyranoside
(IPTG)– inducible T7 RNA polymerase gene in IPTG-induc-
ible form [16]. The primers for mutagenesis were designed
using Vector NTI suite software and mutagenesis was per-
formed by site-directed mutagenesis using a selection primer
and a mutagenic primer. A selection primer 5V-TGAG-
GATCCGAGCTCTAATCTAGAGGCTG CTAAC-3V was
used to introduce XbaI site in pIL13-CLS plasmid in place
of EcoRI site to carry out restriction selection digestion and
transformation in the process of mutagenesis.
The Escherichia coli cells transformed with plasmids were
allowed to grow until A600 reached 2.0. Then the cells were
induced with 250 mM final concentration of IPTG and incu-
bated at 37jC for 2 hours in a 1-l flask with shaking. The
inclusion body pellets were isolated and solubilized in 7 M
guanidine HCl and renatured in the presence of L-arginine
and oxidized glutathione, as described previously [17]. The
renatured proteins were dialyzed against 10 mM sodium
acetate buffer, pH 5.2, and purified on ion exchange columns
SP Sepharose and Mono S (Amersham Pharmacia Biotech)
columns.
SDS-PAGE and Western blot analyses The purity and
molecular weight of the D-helix mutants were verified by
SDS-PAGE under nonreducing conditions. The procedure
for SDS-PAGE has been described elsewhere [18]. All SDS
polyacrylamide gels were 15%. After electrophoresis, the gel
was stained in Coomassie blue. For Western blot analysis,
the proteins were transferred to PVDF membrane using
standard electroblotting procedures. The PVDF membrane
was blocked with 5% nonfat dry milk in phosphate-buffered
saline (PBS) with 0.05%Tween 20 at 4jC overnight. Then the
membrane was incubated at room temperature in 5% milk
containing the polyclonal goat anti–human IL13 antibody
(1:1000 dilution) for 45 minutes. The membrane was washed
three times with 0.05% Tween 20/PBS followed by 45-minute
incubation in 5% milk containing secondary antibody, anti–
goat IgG conjugated to horseradish peroxidase. Subse-
quently, the membrane was washed three times with 0.05%
Tween 20/PBS. The proteins were detected on the film by en-
hanced chemiluminescence (ECL) detection system (Pierce).
Circular dichroism (CD) spectrum analysis The protein sam-
ples used for CD spectrum analyses were dissolved in PBS
(0.1 mg/ml). All the analyses were performed in a quartz
cuvette with a path length of 1 mm using a Jasco (Eden
Prairie, MN) J-710 spectropolarimeter. The spectra were
recorded in the wavelength region of 200 to 260 nm, and
the spectra were subtracted from the blank PBS spectrum.
Cytotoxicity neutralization assay using constant concen-
trations of IL13 mutants The cytotoxicity neutralization ex-
periment was performed as described elsewhere [17].
IL13-PE38QQR is a cytotoxin and fusion protein composed
of IL13 and Pseudomonas exotoxin (PE38QQR), which was
used in the assay [5]. Briefly, 1  103 cells of U-251 MG
cells or 2.5  103 cells of G-26-IL13Ra2+ cells per well
were plated in 96-well culture plates and incubated at 37jC,
5% CO2, and 90% humidity for 24 hours. The receptor sites
on the cells were blocked with IL13 or its mutants, at a final
protein concentration of 1 mg/ml, for 1 hour at 37jC in the
incubator. Subsequently, the cytotoxin, IL13-PE38QQR, was
added at increasing concentrations (0.01–100 ng/ml final
concentration) and the plates were incubated for 48 hours.
Figure 1. Primary structure of IL13, a 114-amino-acid cytokine, with sec-
ondary structure features underlined [23]. Alpha-helical regions A, B, C, and
D of IL13 are in bold face letter whereas interconnecting loops are italicized.
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The proliferated cells in each well were determined by
colorimetric MTS/PMS method, as described [18]. All the
experiments were performed in duplicates.
Cytotoxicity neutralization assay using constant concentra-
tions of IL13-based cytotoxin The assay was performed as
described above except that the inhibitor’s (IL13 or its
mutants) concentrations varied, whereas the concentration
of cytotoxin was constant. The U-251 MG or G-26-IL13Ra2+
cells plated in 96-well plates were blocked with IL13 or its
mutants (0.1–1000 ng/ml final concentration) for 1 hour at
37jC. Then, IL13-PE38QQR at a concentration of 10 ng/ml
was added and incubated at 37jC for 48 hours. Following
incubation, the proliferated cells in each well were deter-
mined by colorimetric MTS/PMS method.
TF-1 cell proliferation (IL13/4R stimulation) assay The prolif-
eration assay was carried out in 96-well culture plates and
the cells were allowed to grow in the presence of different
concentrations of IL13 and its mutants, and incubated at
37jC, 5% CO2, and 90% humidity for 72 hours. The rate of
proliferation was determined by colorimetric MTS/PMS cell
proliferation assay and the absorbency of eachwell at 490 nm
was recorded on a microplate reader. Cells treated with high
concentrations of cyclohexamide served as background for
the assay. The experiment was performed in duplicate.
IL13Ra2 receptor binding analyses In order to establish the
number of binding sites for IL13 on glioma cells, we per-
formed a saturation binding experiment. To establish the
total, nonspecific, and specific binding curves, we added a
range of concentrations of [125I]IL13 or its mutants
(1 pM–2 nM) in the presence or absence of unlabeled IL13
at 400 times molar excess, to 0.5  106 cells (U-251 MG or
G-26-IL13Ra2+ cells). Incubations were carried out at 4jC
for 3 hours. Then the cells were harvested in a cell harvester,
followed by the radioactivity measurement in a g-counter.
The second set of binding assays was performed in the
form of equilibrium competition assays using increasing
concentrations of the unlabeled IL13 or its mutants
(10 pM–10 nM) in the presence of a constant concentration
of the labeled [125I]IL13 (100 pM). For this assay, 0.2  106
cells (G-26-IL13Ra2+ cells) were used. They were incubated
at 4jC for 3 hours, followed by harvesting in a cell harvester
and counting in a g-counter. Analyses of the binding assays
were carried out using the computer program, Graphpad
Prism (San Diego, CA). The Ki values were calculated by the
program Prism using the equation of Cheng and Prusoff [19]:
Ki ¼ EC50
1þ ½ligand=Kd
The Ki value represents an affinity of the radioligand
([125I]IL13) toward the receptor in the presence of competi-
tive inhibitor ligands. Each experiment was performed in
duplicate.
Results and Discussion
Site-Directed Mutagenesis of a-Helix D Residues of Human
IL13
a-Helix D of the IL13 molecule is composed of 24 amino
acid residues. Based on the results of alanine scanning
mutagenesis [18], we have selected residues, which appeared
to be of greatest importance for the binding of IL13 to IL13Ra2,
and mutated them to charged or neutral residues. A series of
single-site mutagenic primers was constructed (Table 1). In
particular, residues Lys-105, Lys-106, and Arg-109 were
substituted for amino acids of varying charge, chain length,
and bulkiness of functional groups. The residues Ala-94 and
Gln-95 were mutated as well because they had displayed a
partial impairment in their ability to interact with IL13Ra2. We
also changed hydroxyproline at position 103 to proline in an
intended helix-destabilizing manner.
Expression and Purification of Recombinant Interleukins
All the expressed proteins in E. coli were localized to the
inclusion bodies and, on average, the yield of all the purified
proteins was found to be 0.5 to 1 mg/liter culture, except for
IL13.K105L, IL13.H103P, and IL13.R109L. IL13 mutant pro-
teins were pure and homogeneous with an approximate
molecular mass of f13 kDa after the purification on SP
Sepharose fast flow and Mono S columns (Figure 2A). All the
mutant proteins were immunoreactive using an anti– IL13
antibody and Figure 2B demonstrates the Western blot of
several representative mutants.
CD Spectrum Analysis of a-Helix D Mutants of IL13
The CD spectra of the studied D-helix mutant proteins
of IL13 were analyzed according to the reported proce-
dure [18]. All the mutant proteins were folded properly into
a-helical enriched structure, as all of them exhibited two
spectral minima at 208 and 222 nm, a characteristic prop-
erty of helical proteins (not shown).
IL13 Mutants Neutralization of Cell Killing by a IL13-Based
Cytotoxin
The cytotoxicity neutralization assay was carried out in
U-251MG andG-26-IL13Ra2+ cells, which express IL13Ra2
either naturally or as a transgene, respectively (Figure 3).
These experiments were performed in order to reveal the
Table 1. Mutagenic Primers Used for a-Helix D of IL13 Mutagenesis.
Position Oligonucleotide Primers (5V to 3V)
A94R ACC-AAA-ATC-GAG-GTG-CGC-TTT-GTA-AAA-GAT
Q95R AAA-ATC-GAG-GTG-GCC-CGC-TTT-GTA-AAA-GAT-CTG
H103P AAA-GAT-CTG-CTC-TTA-CCA-TTA-AAG-AAA-CTT
K105R CTG-CTC-TTA-CAT-TTA-CGC-AAA-CTT-TTT-CGC-GAG
K105E CTC-TTA-CAT-TTA-GAG-AAA-CTT-TTT-CGC
K105D CTC-TTA-CAT-TTA-GAC-AAA-CTT-TTT-CGC
K105L TTC-TTA-CAT-TTA-CTG-AAA-CTT-TTT-CGC-GAG
K106E TTA-CAT-TTA-AAG-GAA-CTT-TTT-CGC-GAG
K106R TTA-CAT-TTA-AAG-CGC-CTT-TTT-CGC-GAG
R109D AAG-AAA-CTT-TTT-GAC-GAG-GGA-CGG-TTC
R109K AAG-AAA-CTT-TTT-AAA-GAG-GGA-CGG-TTC-AAC
R109L AAG-AAA-CTT-TTT-CTG-GAG-GGA-CGG-TTC-AAC
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importance of studied substitution mutants in the a-helix D
region of IL13 in their functional binding toward IL13Ra2.
IL13Ra2 is the receptor that is utilized by the IL13-based
cytotoxin to bind and kill cells [11]. Most of the substitutions
made at Lys-105 in the a-helix D resulted in IL13 mutants
with severely impaired cytotoxicity neutralization efficiency
when compared with wild-type IL13 (Figure 3, A and B). For
example, IL13.K105L and IL13.K105D did not compete for
the receptor sites on the cells that are used by IL13-
PE38QQR cytotoxin, unlike wild-type IL13 (Figure 3, A and
B). This is in line with our earlier study where the replacement
of lysine at position 105 with alanine resulted in total loss of
cytotoxicity neutralization efficiency of the mutant [18]. Sur-
prisingly, substitution of lysine at position 105 to arginine
(IL13.K105R) resulted in a mutant with at least, similar to
wild-type IL13, cytotoxicity neutralization efficiency in the two
studied cancer cell lines (Figure 3, A and B).
Similar to the phenomenon observed with Lys-105, an
anionic glutamic acid substitution at position 106 resulted
in partial loss in cytotoxicity neutralization efficiency of
IL13.K106E in U-251 MG and G-26-IL13Ra2+ cells
(Figure 3, A and B). However, the IL13.K106R mutant was
able to neutralize IL13-PE38QQR cytotoxicity and behaved
similar to wild-type IL13 (Figure 3, A and B). Furthermore,
substitution of arginine at position 109 in a-helix D to other
amino acids, such as leucine and aspartic acid, also resulted
in mutants with altered cytotoxicity neutralization capacities
by displaying a poor neutralization efficiency of IL13-
PE38QQR cytotoxicity in glioma cells (Figure 3, A and B).
Again, substitution of similarly charged lysine in the place of
arginine (IL13.R109K) resulted in an unaltered neutralization
efficiency of the mutant when compared with an intact
cytokine (Figure 3, A and B). Thus, the results obtained with
substitution mutants at positions 105, 106, and 109 are
consistent with the results of the alanine scanning mutagen-
esis studies [18]. Of great interest, we have found evidence
that substitution mutants at position 105 and 109, such as
IL13.K105R and IL13.R109K, resulted in IL13 of high avidity
toward the tumor-associated receptor mutants.
We also made a substitution of alanine at position 94 to
arginine. This substitution did not result in any prominent loss
of cytotoxicity neutralization potential of the mutant in either
U-251 MG cells (Figure 3A) or in G-26-IL13Ra2+ cells
(Figure 3B). However, mutation of glutamine at position 95
to arginine resulted in impaired cytotoxicity neutralization
efficiency when compared with wild-type IL13 (Figure 3, A
and B). Furthermore, the mutant IL13.H103P did not lose all
cytotoxicity neutralization efficiency when compared to wild-
type IL13, which implies that proline at position 103 may not
completely disrupt the helical orientation of a-helix D (Figure
3, A and B).
Titered Cytotoxicity Neutralization Experiment
Next, we performed cytotoxicity neutralization assay in a
reversed scenario: a constant concentration of the cytotoxin
was used instead of serial dilutions (10 ng/ml), and serial
Figure 2. (A) SDS-PAGE analysis (15%) of a-helix D mutants of IL13. Each
well was loaded with 1 g of protein and stained in Coomassie blue. (B) The
Western blot of IL13 a-helix D mutant proteins. The purified recombinant
proteins were resolved on 15% SDS-PAGE and electroblotted to PVDF
membrane. The proteins were detected by ECL detection system.
Figure 3. Cytotoxicity neutralization by IL13 a-helix D mutants in malignant
glioma cells. Neutralizing concentrations of the IL13 mutants were constant
(1000 ng/ml) and the cytotoxin, IL13-PE38QQR, was serially diluted (0.01–
100 ng/ml). Experiments were performed using a colorimetric cell MTS/PMS
proliferation assay. (A) U-251 MG, human GBM cells. (B) G-26-IL13Ra2+,
mouse glioma cells transfected with IL13Ra2. The IC50 for the cytotoxin alone
(no cytokine) was 0.5 and 0.6 ng/ml in U-251 MG and G-26-IL13Ra2+ cells,
respectively. A wild-type IL13, or its mutants with preserved competition for
the receptor used by the cytotoxin, augmented the IC50 values to >100 ng/ml
(e.g., IL13, IL13.K105R, and IL13.K106R neutralized cytotoxicity). The
mutants of IL13 that lost competitive properties did not change or changed
little the IC50 (e.g., IL13.R109D, IL13.K105L, and IL13.K105D).
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dilutions of IL13 mutants were used instead of constant
concentrations (0.1–1000 ng/ml); IL13-PE38QQR cytotoxin
efficiently kills malignant glioma cells at 10 ng/ml. The
cytotoxicity neutralization potential of the wild-type IL13
and its mutants at variable concentrations of the ligand and
at a constant concentration of the cytotoxin is demonstrated
in Figure 4.
In this titered cytotoxicity neutralization experiment, the
highest neutralization efficiency was consistently observed
for IL13K105R. IL13.K105R neutralized the cytotoxicity by
99% at 100 ng/ml concentration when compared with the
mutant’s blocking efficiency at 1000 ng/ml. The wild-type
IL13 and the IL13.K106R and IL13.R109K mutants exhibited
86.5%, 86.7%, and 80.7% cytotoxicity neutralization effi-
ciency, respectively. We then determined effective neutraliza-
tion concentration (ENC) as a minimum concentration of the
cytokine that would bring about 50% of cytotoxicity neutraliza-
tion. ENC was found to be lower for IL13.K105R (10 ng/ml)
than that for the wild-type IL13 (50 ng/ml) (Figure 4). In
addition, IL13.R109K had a strong tendency to neutralize the
cytotoxin at lower concentrations that wild-type IL13, but less
so than IL13.K105R. The least competitive to neutralize the
cytotoxicity of IL13-PE38QQR was IL13.R109K; however, it
was still neutralizing better than wild-type IL13 (Figure 4). This
experiment underlined the better cytotoxicity neutralizing po-
tential of IL13.K105R, IL13.R109K, and IL13.K106R, com-
pared to that seen with wild-type IL13. Thus, these mutants
exhibited an enhanced ability to compete for the receptor sites
used functionally by the IL13-based cytotoxin.
IL13Ra2 Receptor Binding Studies of IL13 D-Helix Mutants
The receptor binding experiments with 125I-labeled IL13
revealed Kd values of 1.4 and 1.3 nM on U-251 MG and
G-26-IL13Ra2+ cells, respectively (Figure 5A). The number
of binding sites per cell was found be 7325 and 14,550,
respectively. Subsequently, we performed studies in which
we examined the competition of IL13 a-helix D mutants with
125I-labeled IL13 for the binding to receptors on G-26-
IL13Ra2+ cells and the results are depicted in Figure 5B.
The binding of [125I]IL13 to the cells was competed for by
IL13.K105R and IL13.R109K, with the EC50 of IL13.K105R
being 0.027 nM and that of IL13.R109K being 0.073 nM,
which is 77- and 27-fold less, respectively, when compared
with wild-type IL13 (2.1 nM) (Table 2). The Ki values of
competitive ligands, namely IL13.K105R, IL13.K106R, and
IL13.R109K, were calculated (Table 2). The results indicate
that IL13.K105R and IL13.R109K are potent competitive
ligands for the iodo–IL13 binding to IL13Ra2, with the Ki
values being 0.025 and 0.068 nM, respectively. However,
Figure 5. Binding studies of IL13 and its mutants to a glioma-associated
receptor for IL13. (A) Saturation curves for [125I]IL13 on U-251 MG cells. (B)
Competition for the [125I]IL13 binding sites by a-helix D mutants of IL13 in
G26-IL13Ra2+ cells.
Figure 4. Cytotoxicity neutralization by IL13 a-helix D mutants in U-251 MG
cells. Wild-type IL13 and neutralizing mutants were serially diluted (0.01–
1000 ng/ml) whereas IL13-PE38QQR concentration was constant (10 ng/ml).
The experiments were performed using colorimetric cell MTS/PMS prolifer-
ation assay. Vertical bars correspond to standard deviation. Higher per-
centage of cells was protected against IL13-PE38QQR cytotoxicity when, for
example, the IL13.K105R mutant was used rather than the wild-type IL13.
Table 2. EC50 and Ki Values for IL13, IL13.K105R, IL13.K106R, and
IL13.R109K Obtained in Receptor Binding Assay in G26-IL13Ra2+ Cells
(Figure 5B ).
IL13
(nM)
IL13.K105R
(nM)
IL13.K106R
(nM)
IL13.R109K
(nM)
EC50 2.134 0.027 3.39 0.073
Ki 2.00 0.025 3.18 0.068
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the Ki value for IL13.K106R was lower than for wild-type IL13
(Table 2). Thus, IL13.K105R and IL13.R109K compete
better for the IL13Ra2 than the wild-type IL13 in receptor
binding experiments.
TF-1 Cell Proliferation Activity of D-Helix Mutants
TF-1 cells are preleukemic human B-cells, which express
the shared IL13/4R, but little, if any, of IL13Ra2 [20]. Hence,
TF-1 cell proliferation assay directly reflects an ability of the
mutants to bind effectively and activate IL13/4R. The TF-1
cell proliferation ability of a-helix D mutants is demonstrated
in Figure 6. The mutant proteins like IL13.K105D,
IL13.K105L, IL13.K105E, IL13.K106E, and IL13.R109D
lacked proliferative activity on TF-1 cells. However, mutants
like IL13.K105R, IL13.K106R, and IL13.R109D proliferated
TF-1 cells similarly to wild-type IL13. Noteworthy,
IL13.K105R, IL13.K106R, and IL13.R109D did not appear
to a have clear-cut superagonistic activities toward IL13/4R.
Triad of Residues in IL13 That Takes Part in the Interaction
with IL13Ra2
Residues Lys-105, Lys-106, and Arg-109 in IL13 are
solvent-accessible and are the most likely residues to be
involved in receptor binding interactions [18]. Furthermore,
these three residues are in close spatial proximity in the
three-dimensional structure of IL13. Our results demonstrate
that residue Lys-105 in the a-helix D region in IL13 is a
receptor contact site as its substitution to uncharged or
negatively charged residues (e.g., leucine, alanine, glutamic
acid, aspartic acid, etc.) resulted in overall loss in their
binding to the glioma-restricted receptor. However, to our
surprise, the substitution of this amino acid with another
positively charged amino acid, arginine, resulted in a mutant,
which binds IL13Ra2 more competitively when compared
with wild-type IL13. Thus, substitutions with glutamic acid,
leucine, and aspartic acid likely distort the recognition
site, resulting in an impaired binding affinity for the receptor,
whereas substitution with positively charged arginine results
Figure 6. Proliferative (IL13/4R-stimulating) potency of the a-helix D mutants
on TF-1 cells. Experiments were performed using a colorimetric MTS/PMS
cell proliferation assay.
Figure 7. Main structural features of IL13 (a-helix A, C, and D are seen). The residues that contribute to receptor binding site I (Glu-13, Arg-66, and Ser-69) are
shown in green (Ser-69 is hidden behind a-helix C). The residues that contribute to receptor binding site II (Lys-105, Lys-106, and Arg-109) are shown in yellow.
Sites I and II take part in the binding of IL13 to IL4Ra and IL13Ra protein chains, respectively.
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in an enhanced avidity. It is plausible that the contact sites in
the IL13Ra2 protein involve negatively charged residue(s) or
neutral residue(s). It is also noteworthy that the large resi-
dues, such as arginine, contribute to the higher side-chain
flexibility of the ligand–receptor interface [21].
Figure 7 indicates the orientation of receptor binding
residues in a-helix A, B, and C in IL13. Our previous studies
demonstrated that IL13.E13K in A-helix and IL13.R66D and
IL13.S69D in C-helix retained an ability to interact with
IL13Ra2, but not with the shared IL13/4R, which is com-
posed of IL4Ra and IL13Ra1. Thus, we conclude that the
residues Glu-13, Arg-66, and Ser-69 are the contact resi-
dues with IL4Ra, and Lys-105 and Arg-109 in the C-terminal
region of IL13 are the contact residues with IL13Ra2
(Figure 7). The IL4Ra receptor and the IL13Ra2 interacting
residues lie, respectively, at receptor binding site I (yellow)
and receptor binding site II (green) in the IL13 molecule, as
shown in Figure 7.
In order to further visualize the function of Lys-105 and
Arg-109 residues in IL13 binding to IL13Ra2, we modeled
the structural side-chain changes at position 105 upon
substitution with various amino acids using Swiss-PDB mo-
lecular viewer and the coordinates available from the solution
structure for IL13, as presented in Figure 8 [22,23]. The
proximity between the side chain –NH2 group (residue 105)
and –C (NH2)NH– group (residue 109) and their orientation
is shown in Figure 8. It is plausible that such orientation
favors the residues to anchor the receptor site coordinately
and that this is achieved more optimally in the IL13.K105R
version of the cytokine (Figure 8B). All the other mutants,
namely IL13.K105E, IL13.K105D, IL13.K105A, and
IL13.K105L did not have the extended side chain at position
105 in order to provide hypothetically required optimal space
for the interaction with the receptor (e.g., IL13.K105E in
Figure 8C). Thus, we propose that IL13 interacts with
IL13Ra2 coordinately through positions 105 and 109, pro-
viding an ambient anchoring toward IL13Ra2.
Conclusion
The a-helix D mutants of IL13, IL13.K105R, and IL13.R109K
were found to bind IL13Ra2 better than the native protein.
The most plausible explanation for this phenomenon is the
orientation and alignment of positions 105 and 109 in the
a-helix D region toward the receptor engagement. Thus, we
identified mutants of IL13 having desired characteristics for
future development of tumor targeting molecules while spar-
ing normal organs [15]. Previously, we presented evidence
for IL13Ra2 being a unique molecular target in cancer [11].
Several therapeutic approaches that target this receptor,
including vaccines [24], gene therapy [25], passive immuno-
therapy represented by retargeted cytotoxic T cells [26], and
new IL13-based cytotoxins [12,27], are being developed
preclinically and clinically. New mutant proteins of IL13 will
facilitate achieving the goal of developing agents of specific
targeting properties to the tumor-associated receptor,
IL13Ra2.
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